Litcius/Paper detail

Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Ahmed Hassan Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Lamis Ahmed Fahal, Abubakar Ahmed Mohamed, El Semani Widaa Mohamedelamin, Mustafa El Nour Bahar, Hadil Yassir Attalla, Emmanuel Edwar Siddig, Najwa A. Mhmoud, Ahmed Musa, Wendy W. J. van de Sande, Bruno Scherrer, Peelen Oyieko, Thaddaeus Egondi, Kevin Onyango, Katsura Hata, Wan‐Yu Chu, Thomas P. C. Dorlo, Roger J. M. Brüggemann, Borna Nyaoke, Nathalie Strub‐Wourgaft, Eduard E. Zijlstra

2024The Lancet Infectious Diseases27 citationsDOIOpen Access PDF

Topics & Concepts

MedicineItraconazoleDouble blindProof of conceptInternal medicineTraditional medicineSurgeryDermatologyPlaceboAntifungalAlternative medicinePathologyComputer scienceOperating systemActinomycetales infections and treatmentInfectious Diseases and MycologyFungal Infections and Studies
Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial | Litcius